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Introduction
History of Opioids1,2
The ancient Sumerians (4000 B.C.) and Egyptians (2000 B.C.) may have
known the psychological effects of opium and its usefulness in controlling pain and
diarrhea, but the first undisputed reference to this juice of the poppy Papaver
sominiferum is from the Greeks in 3 B.C. Over the years opium was used for medicinal
purposes in Arabia, the Orient, Europe, and to some extent the United States. How-
ever, with unrestricted availability came abuse and addiction to opium and its main active
ingredient morphine. While morphine is still one of the most effective and widely used
pain-relieving drugs, its undesirable side effects (respiratory and pulmonary depression,
constipation, and abuse potential) have stimulated a large research effort to develop non-
addictive analgesics. Although this has not been achieved, many clinically useful drugs
have been produced. More importantly, this research has resulted in the discovery of
multiple opioid receptors and endogenous opioid peptides in vertebrate animals inclu-
ding humans. With more knowledge of the structure, conformation, and biochemistry
of these peptides and receptors perhaps someday a non-addictive opioid analgesic
without these side effects will be developed.
Opioid Receptors and Opioid Action
Multiple Opioid Receptor Types
The first proposal of a receptor for opiates was by Beckett and Casy,
based on activities of stereoisomers.3 Many years later Martin's lab proposed the
existence of three different receptor types, mu (t), kappa (x), and sigma (a), to explain2
the different behavioral and physical effects of morphine, ketazocine, and N-allyl-
normetazocine, SKF 10,047, in chronic spinal dogs.4.5 The effects seen with morphine
administration included analgesia, miosis, bradycardia, hypothermia, and indifference to
environmental stimuli. Ketazocine caused miosis, general sedation, and depression of
flexor reflexes, while SKF 10,047 caused mydriasis, increased respiration, tachycardia,
and delirium. Since then, the a receptor has been designated non-opioid because the
behavioral effects induced by its ligands (benzomorphans) are not blocked by naloxone,
a high affinity antagonist often used to define compounds as opioids.6,7 A true third
opioid receptor is the delta (6) receptor type, which is antagonized by naloxone and dis-
tinctly differs from IA, or lc receptors 8,9
Although antagonism by naloxone has been traditionally used to characterize
opioid receptors, there are other ligands now being used to characterize the different
receptor types (Table 1).10,11
Location of Receptors
The locations of .t, 6, and x opioid receptors have been studied in tissues
of several species using autoradiographic techniques. A tritiated general opioid ligand is
added to the tissue slices, then a ligand specific for one receptor type is added and its
ability to displace the general ligand is measured for quantitative results. Opioidrecep-
tors have been found to be located in physiologically relevant areas of both the central
nervous system (CNS) and peripheral tissues. In rat and guinea pig, tt receptors are
found in many parts of the CNS including the pyriform cortex,12 layers III-VI of the
cerebral cortex, N. accumbens, amygdala, olfactory bulb, striatal patches and streaks,13
cingulate and medial frontal cortex, hippocampal pyrimidal layer, thalamic basolateral
nucleus, lateral septum, colliculi, substantia nigra, and periaqueductal grey.14 Murecep-
tors are found in other tissues as well, a notable one being the cerebellum in rabbits.153
Table 1.Opioid Ligands Used To Characterize Opioid Receptors k
Receptor Type
5
K
Agonist Antagonist
DAMGO naloxone
dermorphinB naltrexone
DADLE ICI 174,864
DSLET, DTLET naltrindole
DPDPE
deltorphinB
bremazocine Nor-BNI
U 50,488, U 69,593
A All compounds in Table 1 are from ref. 10 unless otherwise indicated.
B From ref. 11.4
Delta receptors, likewise, are found in several areas of the CNS including the
caudate nucleus,12 and layers I, II, V, and VI of the cerebral cortex, neocortex,
olfactory bulb, N. accumbens, amygdala, and striatum.13 There is a lack of 6 receptors
in the midbrain, hindbrain, and thalamic nuclei.14
In both rat and guinea pig brain lc receptors are found in layers V and VI of the
cerebral cortex,12 olfactory bulb, N. accumbens, striatum, and substantia nigra.I4 In
guinea pig lc receptors are also found in the pyriform cortex and low levels in the
thalamic and hypothalamic nuclei.14 The opioid receptors in the guinea pig cerebellum
are almost all of the K type.16 In rat brain K receptors are found in relatively low levels
in the central grey and the thalamic and hypothalamic nuclei.14 Kappa receptors are
found in relatively high levels in the spinal cord17 and human placenta.18,I9
Of pharmacological importance, all three receptor types are found in the mouse
vas deferens, and lit and ic receptors are located in the guinea pig myenteric plexus
(guinea pig ileum GPI).20 Opioid receptors in the rabbit and hamstervas deferens are
almost all of the K21 and 622 types, respectively.
Actions of Opioid Agonists
The most notable action of opioid drugs in humans at any receptor type is
analgesia. At theµ receptor, morphine and otherµ agonists produce analgesia atsupra-
spinal sites. Other effects of iLt receptor activation include reduced gonadotropin and tes-
tosterone levels,23 respiratory and cardiovascular depression, miosis, reduced gastro-
intestinal (GI) motility, euphoria, and high abuse potentia1.24 Kappa selective agonists
act in the spinal cord to produce analgesia and antinociception for long term inflamma-
tory pain25 and nonthermal noxious stimuli,26 with less respiratory depression, constipa-
tion, miosis, and abuse liability compared to [I, agonists.27 However, K-mediated action
produces dysphoric, psychotomimetic effects rather than euphoria.27 The results of 65
receptor activation are not well defined in humans because the specific 6 ligands do not
cross the blood-brain barrier. Analgesia and positive reinforcing effects at supraspinal
sites, antinociception for thermal stimuli at spinal sites, and cardiovascular depression
are the effects caused by specific 6 agonists administered in animals.213,29
Mechanisms of Action
It has been proposed that opioids acting on all three receptor types have
two distinct biochemical actions. First, when the receptors are located at the presynaptic
area of the nerve, opioids act as neuromodulators, resulting in decreased release of
excitatory neurotransmitters (see Fig. 1).1 Mu receptor activation in rat brain cortical
slices inhibits norepinephrine30 and acetylcholine turnover,31 while in rat brain striatal
slices activation of ic receptors inhibits dopamine release and 6 receptor activation
inhibits acetylcholine release.30
In rats, IA, ic, and 6 receptors also act as neuromodulators in the hypothalamic-
pituitary-adrenal axis to modulate an increase in the anterior pituitary hormones pro-
lactin,32 growth hormone,32 corticosterone,33.34 and ACTH,3334 and a decrease in
thyroid stimulating hormone (TSH), the gonadotrophins, and the posterior pituitary
hormones vasopressin and oxytocin.32 In humans the actions of exogenously
administered opioids are the same, except that the level of TSH is elevated.32
Second, when the receptors are located postsynaptically, activation of 1.1. and 6
receptors inhibits adenylate cyclase.1-30 This may lead to increased outward K+
conductance through Ca2+-activated K+ channels resulting in hyperpolarization of the
cell and a decrease in Ca2+ flux.1,9 Activation of lc receptors leads directly to a
reduction of Ca2+ conductance due to the closing of voltage-dependent N-type Ca2+
channels.1,2 G-proteins may be involved in the coupling of opioid binding sites to ion
channels; the hydrolysis of phosphoinositides is another possibility.26
Fig. ISchematic Representation of a Possible Mechanism for
Opiate-Induced Suppression of Substance P (SP)
Release.
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SP is shown localized within athe terminal of a small- diameter afferent fiber which forms
an excitatory axodendritic synapse with the process of a spinal cord neuron originating in
lamina IV or V and projecting rostrally. A local enkephalin-containing inhibitory interneuron
(ENK), confined to laminae H and III, forms a presynaptic contact on the terminal of the
primary afferent. Opioid receptors are depicted presynaptically. From Simon, E J. Med.
Res. Rev. 1991, 11, 357-374.7
Opioid Peptides
Endogenous Opioid Peptides
There are three families of peptides that have been isolated, characterized,
and identified as endogenous opioid peptides in mammals: the enkephalins, endorphins,
and dynorphins. These are derived from the proteolytic cleavage of the precursor
proteins proopiomelanocortin (POMC), proenkephalin, and prodynorphin9 (see Fig.
2).2 POMC is formed mainly in the pituitary and its primary opioid product is 13-
endorphin, which is located in the pituitary with smaller amounts in the hypothalamus,
pancreas, gastric antrum, and the placenta 35,36 (3-Endorphin is equipotent at both 6 and
receptors.37 POMC contains many nonopioid peptides including ACTH as well.
Proenkephalin, formed in the adrenal medulla and striatum,38 contains four copies of
Met-enkephalin, two copies of extended Met-enkephalin, and one copy of Leu-
enkephalin,' all of which show a high preference for 6 receptors. The enkephalinsare
located in various sections of the brain, autonomic ganglia, GI tract, reproductive
organs, and adrenal medulla.9 Prodynorphin, isolated from brain, spinal cord,
pituitary, adrenals, and reproductive organs,' is the source of dynorphin A (Dyn A) and
its 1-8 and 1-9 fragments, which act at x receptors.39 These peptidesare located
primarily in the spinal cord, parts of the brain, and the GI tract.37 Other opioid peptides
formed from prodynorphin are a- and (3- neoendorphin and Dyn B.'
Dynorphin A and Structure-Activity Relationship Studies
Dynorphin A (Dyn A) was first identified and isolated from porcine
pituitary.40 It is a potent opioid peptide that interacts preferentially withx opioid
receptors, and thus Dyn A has been postulated to be an endogenous lc ligand.41 Dyn A
is a 17-amino acid peptide (Fig. 3) with two distinct regions. The N-terminal
tetrapeptide "message" is identical to that of other mammalian opioid peptides, while theFig. 2Schematic Representation of the Structures of the
Precursors of the Three Families of Opioid Peptides.
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C-terminal "address" is unique to Dyn A.42 A few studies have been done to determine
the importance of individual residues for opioid potency and receptor selectivity (see
Chapter I).
Many attempts have been made to determine the structural conformation of Dyn
A using physical methods such as NMR, IR, Raman, and fluorescent spectroscopies in
different media (see Chapter II),43-50 but no one conformation can be agreed upon.
Because opioid receptors are not present in these physical measurement experiments, the
biologically active conformation of Dyn A may not be found by these means. Another
method to determine biologically active conformations of a peptide is to prepare
conformationally constrained analogues. A region of the peptide is modified in order to
disallow specific bond rotations and constrain the peptide to a limited number of
possible conformations. Common constraints involve replacing sections of the peptide
backbone with rigid entities or cyclizing from side-chain to side-chain, side-chain to
backbone, side-chain to terminus, or terminus to backbone. The first analogues of Dyn
A constrained in the "message" sequence, cyclo[D-Cys2,Cys5]Dyn A-(1-13)51 and
cyclo[D- Orn2,Asp5] -Dyn A-(1-8),52 show high potency in the GPI, but also exhibit
high ti-receptor affinity. The other reported cyclic analogues of Dyn A, cyclized via a
lactam, cyclo[Orn5,Asp8] -, cyclo[Orn5,Asplo[-, and cyclo[Orn5,Asp13[Dyn A -(1-
13),52 or via a disulfide, cyclo[Cys5,Cys11]-, and cyclo[Cys5,Cys11,D-Ala81Dyn A-(1-
1 1)NH2, and cyclo[Cys8,Cys13] -, cyclo[D-Cys8,Cys13[-, and cyclo[D-Cys8,D-
Cys13[Dyn A-(1-13)NH2,53 are constrained in the C-terminal "address" portion of the
peptide. The cyclic lactam derivatives are all selective for R-opioid receptors, while the
cyclic disulfide peptides have high binding affinities for bothµ and -lc receptors. The
only reported Dyn A analogues conformationally constrained in the "message" sequence
with selectivity for x receptors are described in Chapter II.11
Solid-Phase Peptide Synthesis54
Solid-phase peptide synthesis (see Fig. 4), devised by R.B. Merrifield in
1963,55 revolutionized peptide chemistry by eliminating the necessary isolation of
peptide products and most of the solubility problems found with solution synthesis. In
solid-phase synthesis, the growing peptide chain is attached to an insoluble support
resin which can easily be rinsed and filtered free of soluble by-products and excess
reagents while retaining the peptide. A resin consists of a polymeric solid support
which is functionalized with an anchor group to which a linker specific to the type of
chemical protocol used is attached. The resin I used in synthesis was the PAL® (peptide
amide linker) resin which consists of a polystyrene support that is functionalized with a
methylbenzhydryl amine (MBHA) anchor with the 9-fluorenylmethyloxycarbonyl
(Fmoc)-protected PAL' -1) linker attached (see Fig. 5). The peptide is removed from the
PAL resin with trifluoroacetic acid (TFA) to give the peptide amide. The peptide amide
is prepared because it is more stable in biological assays to both endo- and exopeptidase
enzymatic degradation than the free acid.
The amino acids used in peptide synthesis must have the amino group and
reactive side-chain groups protected so that no undesired reactions occur as the amino
acids are coupled sequentially to the growing peptide chain. The first chemical
methodology for protection during solid-phase synthesis was the tert-butyloxycarbonyl
(Boc) protocol. The Boc group protects the amine group of the amino acid being
coupled at its carboxyl end to the growing peptide. The Boc group is removed with a
mild to moderate acid (HC1 in acetic acid or TFA) before coupling of the next amino
acid. Therefore, the reactive side chains of the amino acids must be protected with much
more acid-stable groups. Amine, acid, or hydroxyl functions are protected via a benzyl
ester or benzyl ether, while the other reactive functions require more specialized
protecting groups. To form the new peptide bond, the coupling agents dicyclohexane-12
Fig. 4 Solid-Phase Peptide Synthesis
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or diisopropylcarbodiimide are often used, although there are other methods including
several newer ones. When the desired peptide chain is complete, it is normally cleaved
from the resin, with a strong acid (liquid HF or HBr in acetic acid), and the side chain
protecting groups removed at the same time. The disadvantages of this synthetic
strategy stem from the necessity of using weak acid for the a-amino deprotection and a
very strong acid for the final deprotection and cleavage. The weaker acid used to cleave
the Boc group may cause premature deprotection of a small percentage of the side chains
and some cleavage from the resin, resulting in unwanted side products. The strong
acids are not only unpleasant and dangerous to handle, but they require special
apparatus, and cause undesirable side reactions at specific amino acids.
The Fmoc protocol for solid-phase synthesis has gained in popularity over the
Boc chemistry because it has eliminated some of the undesirable problems found in the
latter. A strategy of orthogonal protection, the Fmoc protocol allows the amino protect-
ing group (Fmoc) to be removed by weak organic base (piperidine) in preparation for
coupling to the next amino acid, while the side-chain protecting groups remain in place.
Side chain amines, acids, and hydroxyls are protected by t-butyl derivatives to form acid-
labile urethane, ester, and ether linkages, respectively, while other reactive side chains
are protected by specialized protecting groups such as 2,2,5,7,8-pentamethylchroman-6-
sulfonyl (Pmc) used for Arg (see Chaps. I and II). The coupling agents used are the
same as in the Boc protocol. After the peptide with the desired amino acid sequence is
complete, it is cleaved from the resin by acid (TFA); the side-chain protecting groups
are also removed in this step. Although there are great advantages of orthogonal
protection there are still side reactions specific to some amino acids that one must be
aware of. Using a scavenger cocktail during cleavage can keep these to a minimum.15
Chapter I
Effect of Modification of the Basic Residues of Dynorphin A-(1-13)
Amide on Kappa Opioid Receptor Selectivity and Opioid Activity§A
Kristin R. Snyder,+ Sandra C. Story,+ Mia E. Heidt,± Thomas F. Murray,+Gary E.
DeLander,+ and Jane V. Aldrich+#*
+College of Pharmacy and #Center for Gene Research and Biotechnology, Oregon State
University, Corvallis OR 97331
(* to whom correspondence should be addressed)
§ A preliminary report on this research was presented at the 22nd National Medicinal
Chemistry Symposium, Austin, Texas, July 29-August 2, 1990.
As published in the Journal of Medicinal Chemistry, 1992, 35, 4330-4333.16
A Abbreviations
Abbreviations used for amino acids follow the rules of the IUPAC-IUB
Commission of Biochemical Nomenclature in J. Biol. Chem. 1972, 247, 977-983.
Amino acids are in the L-configuration. Additional abbreviations used are as follows:
Boc, tert-butyloxycarbonyl; DAMGO, [D-Ala2,MePhe4,Glyol]enkephalin; DCM,
dichloromethane; DIC, diisopropylcarbodiimide; DMA, N,N-dimethylacetamide;
DMF, N,N-dimethylformamide; DPDPE, [D- Pen2,D- Pen5]enkephalin; Dyn A,
dynorphin A; FAB-MS, fast atom bombardment mass spectrometry; Fmoc, 9-
fluorenylmethoxycarbonyl; GPI, guinea pig ileum; HOBt, 1-hydroxybenzotriazole;
HPLC, high performance liquid chromatography; Lys(Ac), NE-acetyllysine; MBHA,
4methylbenzhydryl-amine; Pmc, 2,2,5,7,8-pentamethylchroman-6-sulfonyl; TFA,
trifluoroacetic acid.17
Abstract
A series of dynorphin A-(1-13) amide (Dyn A (1-13)NH2) analogues containing
lysine or NE-acetyllysine (Lys(Ac)) was prepared by solid-phase peptide synthesis and
evaluated for opioid receptor affinity in radioligand binding assays and for opioid
activity in the guinea pig ileum (GPI). Substitutions were made at positions 6, 7, 9, 11,
and 13, the basic amino acids in the C-terminus of the peptide, in order to assess the
individual contributions of these residues to the lc opioid receptor affinity and selectivity
of Dyn A-(1-13)NH2. While substitutions of Lys(Ac) for Arg in position 6 did not
affect lc receptor affinity, it enhanced affinity for 1.1 and 6 receptors and therefore caused
a loss of x receptor selectivity. When Lys(Ac) was substituted for Arg9, tc opioid
receptor affinity was enhanced and lc receptor selectivity was retained. Replacement of
Are, Lys11, or Lys13 by Lys(Ac) resulted in both decreased affinity and selectivity for
lc receptors. These results demonstrate the importance of Arg6 to the receptor selectivity
profile of Dyn A-(1-13)NH2 and indicate that of the five basic residues in the C-
terminus, only Arg9 can be replaced by a nonbasic residue without substantial loss of
opioid receptor selectivity.18
Introduction
Dynorphin A (Dyn A), originally isolated from porcine pituitary,40 is postulated to
be an endogenous x opioid receptor ligand.42 Dyn A shares a common N-terminal
tetrapeptide sequence (the "message" sequence) with other mammalian opioid peptides,
while containing a unique C-terminal "address" sequence which imparts selectivity for
opioid receptors.41 The shortened Dyn A-(1-13), with the sequence Tyr-Gly-Gly-Phe-
Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys, accounts for essentially all of the biological
activity of Dyn A in the guinea pig ileum (GPI) assay.56
Shortly after the determination of the sequence of Dyn A-(1-13), studies were
undertaken to determine which amino acids in the C-terminal "address" region of the
peptide are important for opioid potency and tc receptor selectivity. The first of these
involved successive truncation of Dyn A-(1-13) from the C-terminus and the evaluation
of the fragments in the GPI.41 This study found that the basic residues Arg7, Lys11,
and Lys13 were important residues for potency. Based upon the sensitivity of the
fragments to antagonism by naloxone, it was concluded that Are and Lysll made the
greatest contributions to x receptor selectivity. In another study, Dyn A and related
fragments Dyn A-(1-13), -(1-11), -(1-9), -(1-7), and -(1-5) were tested in ileum
preparations made tolerant to morphine or ethylketocyclazocine.S7 While the extension
of Leu-enkephalin by the two basic residues in positions 6 and 7 conferredsome
dynorphin-like properties to the peptide, the longer fragments Dyn A-(1-11) and Dyn A-
(1-13) exhibited the greatest preference for lc receptors. Because fragmentswere used in
both of these studies, however, the contributions of individual C-terminal residues tolc
opioid receptor selectivity and potency could not be separated from the effects of
previously truncated residues. In particular, the contribution of Arg6 tolc receptor
selectivity could not be determined, since truncation of the important Arg7 residue
results in a peptide, Dyn A-(1-6), which no longer exhibits selectivity forlc receptors.19
The contribution of individual residues to potency and receptor selectivity can be
assessed by amino acid substitution in the peptide. In one study, alanine was
systematically substituted for each amino acid in positions 1 through 11 in Dyn A -(1-
13).58 The analogues were evaluated for opioid activity in smooth muscle assays and for
opioid receptor affinity in a [3H]etorphine binding assay in rat brain. From this study
the most important sites in the "address" portion for potency appeared to be Arg6 and
Arg7, with Arg9 and Lys11 making smaller contributions. No information was
reported, however, on what effects these substitutions had on selectivity for ic receptors.
We are interested in preparing a variety of Dyn A analogues, including
conformationally constrained derivatives, with enhanced selectivity for x opioid
receptors. While the contributions of Arg7 and Lysll to Dyn A's potency and selectivity
are generally accepted, the relative importance of the basic residues in positions 6 and 9
are less clear. Thus these latter two positions could be potential sites for incorporation
into a conformational constraint or other structural modification. Incorporation intoa
conformational constraint such as a lactam or cyclic disulfide would entail the loss of the
residue's basicity. Therefore we investigated whether either of these positions could be
replaced by a nonbasic residue by preparing linear analogues containing NE-acetyllysine
(Lys(Ac)) in each of these positions. We also substituted Lys(Ac) for the basic residues
in positions 7, 11 and 13 in Dyn A-(1-13)NH2. This allowed us to evaluate the relative
importance for lc opioid receptor selectivity and potency of residues 6 and 9as compared
to residues 7, 11 and 13. We used the peptide amide because Dyn A-(1-13)NH2 retains
the lc receptor selectivity of the corresponding acid and is more stable to enzymatic
degradation.59 Since arginine is normally present in positions 6, 7 and 9 in Dyn A -(1-
13), the analogues containing lysine in these positions were also prepared to allow fora
more direct comparison to the acetylated analogues.20
Results
Peptide Synthesis and Purification. All peptides were synthesized on a
PAL resin (a 4- methylbenzhydrylamine (MBHA) resin with a 544-(aminomethyl)-3,5-
dimethoxyphenoxyi-valeric acid linker60) using (9-fluorenylmethoxy)carbonyl (Fmoc)
protected amino acids. Side-chain protecting groups used in this synthetic strategy were
tert-butyloxycarbonyl (Boc) for Lys, 2, 2, 5, 7, 8- pentamethylchromanyl- 6- sulfonyl
(Pmc)61 for Arg, and tert-butyl (tBu) for Tyr. The Fmoc-protected amino acids were
coupled to the growing peptide chain using diisopropyl-carbodiimide (DIC) and 1-
hydroxybenzotriazole (HOBt) in DCM/DMF or DCM/DMA (1/1). The Fmoc protecting
group was removed with 30% piperidine in DMF/toluene or DMA/toluene (1/1). The
peptides were deprotected and cleaved from the PAL resin using concentrated
trifluoroacetic acid (TFA) in the presence of scavengers (generally Reagent K62) and
purified by preparative reverse phase HPLC. The purified peptides were characterized
by analytical HPLC, fast atom bombardment mass spectrometry (FAB-MS), and amino
acid analysis (Tables 2 and 3).
Opioid Receptor Binding Affinities and Opioid Activity. The peptides
were evaluated for opioid receptor affinity at lc,and ö receptors by measuring the
inhibition of binding of [3H]bremazocine, [3H]DAMGO ([13-Ala2,MePhe4,Glyol]-
enkephalin),63 and [3H]DPDPE ([ D-Pen2,D-Penslenkephalin),64,65 respectively (Table
4), as previously described.66 Kappa opioid receptor affinity was determined in the
guinea pig cerebellum, since over 80% of the opioid receptors in this tissue are ic
receptors.16 Mu and to opioid receptor affinities were assessed in rat forebrain
membranes. The opioid activity of the peptides was determined in the electrically-
stimulated GPI66 (Table 5).Table 2.Yields, HPLC Analysis, and Fast-Atom Bombardment Mass
Spectrometry (FAB-MS) Analysis of [Lys]- and [Lys(Ac)]Dyn A-
(1-13)NH2 Analogues
Dyn A- (1- 13)NH2
Analogue % Yield
HPLC
FAB-MS
M+1
Gradienta
R, in mL
Isocratic
Rv in mL (%B)b
Lys6 37 31.4 19.8 (16%) 1575
Lys(Ac)6 45 30.0 16.8 (16%) 1617
Lys? 8c 29.4 11.9 (17%) 1575
Lys(Ac)7 49 30.2 11.2 (19%) 1617
Lys9 81 27.9 16.2 (18%) 1575
Lys(Ac)9 56 30.5 22.2 (18%) 1617
Lys(Ac) 11 26 30.6 7.5 (15%) 1645
Lys(Ac) 13 40 30.1 11.9 (19%) 1645
a 0 to 75% B over 50 min at 1.5mL/min.
b solvent composition indicated in parentheses
c yield low due to procedural losses during purificationsee experimental section22
Table 3.Amino Acid Analysis of [Lys]- and [Lys(Ac)]-
Dyn A-(1-13)NH2 Analogues
Analogue Y(1)G(2)EliL(2)R(2/3),la)P(1)K(2/3)
Lys 6 0.952.000.982.032.100.931.033.01
Lys(Ac)60.862.030.961.962.120.860.213.02
Lys? 0.881.940.962.102.011.081.182.85
Lys(Ac)70.991.970.981.972.070.951.122.97
Lys9 0.892.031.002.142.041.071.062.78
Lys(Ac)90.872.060.982.142.041.041.092.79
Lys(Ac)11 0.892.060.992.182.941.001.04 1.91
Lys(Ac)131.021.961.011.983.070.931.021.99Table 4.Oploid Receptor Binding Affinities and Selectivities of [Lys]. and [Lys(Ac)]Dyn A-(1-13)NH2 Analogues
Peptide
(nM)
Receptor Selectivity (K/u/Ola LaillBremazocine LaHlDAMGO L.4.111DPDPE
Dyn A-(1-13)NH20.023 -10.009 0.4010.06 1.9 10.2 1 / 18 / 83
Ly s6 0.020 -± 0.005 0.075 ±. 0.018 5.9 ± 1.7 1 / 3.9 / 300
Lys(Ac)6 0.024 ±. 0.003 0.018 ± 0.003 0.42 ± 0.11 1.3 / 1 / 23
Lys? 0.021 ±.0.001 0.055 ± 0.006 1.6 ± 1.4 1/ 2.6/78
Lys(Ac)7 0.14 ± 0.06 0.18 ± 0.02 1.1 ±0.2 1 / 1.3 / 7.7
Lys9 0.0067 ± 0.0010 0.046 -± 0.005 1.9± 0.4 1/6.9/400
Lys(Ac)9 0.0042 L. 0.0013 0.043 ±. 0.008 1.3 -±. 0.2 1 / 10.4 / 490
Lys(Ac)I1 0.053 ± 0.017 0.030 ± 0.001 0.451: 0.27 1.8 / 1 / 15
Lys(Ac) 1 3 0.15 ± 0.06 0.061 ± 0.004 4.61- 0.7 2.4 / 1 / 75.
a Ratio of Ki's where the lowest K1 is used as thedenominator24
Table 5.Opioid Activity of [Lys]- and [Lys(Ac)]Dyn A(1- 13)NH2
Analogues in the Guinea Pig Ileum
Dyn A(1- 13)NH2 IC50 in nM (95%
Analogue Confidence Interval) Relative Potency ( % )
Dyn A-(1-13)NH2 0.24 (0.21-0.29) 100
Lys6 0.25 (0.13-0.50) 94
Lys(Ac)6 0.64 (0.31-1.34) 37
Lys? 0.19 (0.13-0.29) 122
Lys(Ac)7 0.34 (0.26-0.45) 69
Lys9 0.27 (0.19-0.37) 89
Lys(Ac)9 0.26 (0.18-0.38) 91
Lys(Ac)ii 0.16 (0.12-0.21) 148
Lys(Ac)I3 0.19 (0.14-0.24) 12625
Replacement of the arginines at positions 6,7 and 9 in Dyn A-(1-13)NI-12 by
lysine generally caused the greatest changes in receptor affinity atµ receptors, where
receptor affinity was enhanced 5- to 22-fold compared to Dyn A-(1-13)NH2 (Table 4).
The affinity for x receptors was unchanged when the arginines at positions 6 and 7 were
replaced by lysine, while substitution of lysine for Arg9 increased lc receptor affinity 3-
fold when compared to the parent peptide. The net result was a loss of discrimination
between x and 1.1 receptor binding for all three of the analogues. The substitution of
lysine in positions 7 and 9 had little effect on the analogues' affinity for 6 receptors,
while [Lys6]Dyn A-(1-13)NH2 exhibited decreased affinity for 6 opioid receptors.
[LysiDyn A-(1-13)NH2 thus showed discrimination between tc and 6 opioid receptors
similar to that of the parent peptide, while [Lys6]- and [Lys9]Dyn A-(1-13)NH2 showed
improved discrimination between x and 6 receptors compared to Dyn A-(1-13)NH2.
The positive charge at each of positions 6, 7, 9, 11, and 13 was removed by
acetylating the side-chain amine of lysine. Unlike replacement of Arg6 by Ala, which
decreases opioid receptor affinity in rat brain,58 acetylation of lysine in position 6 had
little effect on lc receptor affinity. It enhanced 1..t binding affinity, however, causing a
complete loss of x receptor selectivity. When the 7 position was acetylated, lc binding
showed a 6-fold decrease while Ix binding decreased only 3-fold, so discrimination
between the two receptor types was again nonexistent. Binding affinity for x receptors
decreased 2-fold and 6-fold for [Lys(Ac)11]- and [Lys(Ac)13]Dyn A-(1-13)NH2,
respectively, while the affinity of these peptides for it receptors increased 6- to 13-fold,
so that they exhibited a slight preference forµ over x receptors. The one exception to
this loss of tc selectivity was [Lys(Ac)9]Dyn A-(1-13)NH2, which showed enhanced lc
receptor affinity and selectivity compared to its parent, [Lys9]Dyn A-(1-13)NH2, and
was the most tc selective of the Dyn A-(1-13)NH2 analogues prepared. The marked
enhancement in affinity for lc and ti receptors by [Lys(Ac)9]Dyn A-(1-13)NH2 over Dyn26
A-(1-13)NH2 is in contrast to the modest decrease in affinity observed for [Ala9]Dyn A-
(1-13) in [3H]etorphine binding assay in rat brain.58
Acetylation in the 6, 7 and 11 positions enhanced affinity for 6 receptors, and
thus decreased the discrimination between ic and 6 receptors for these peptides.
Interestingly, acetylation of Lys13 decreased affinity for 6 opioid receptors, but because
of this analogue's decreased affinity for x receptors its discrimination between tc and 6
receptors was very similar to that of Dyn A-(1-13)NH2. While acetylation at the 9
position slightly increased 6 opioid receptor affinity, the marked enhancement in the tc
receptor affinity of [Lys(Ac)9]Dyn A-(1-13)NH2 increased its discrimination for lc over
6 receptors, similar to its parent peptide [Lys9]Dyn A-(1-13)NH2.
All of the analogues exhibited subnanomolar potency in the guinea pig ileum
(Table 5). Only [Lys(Ac)6]Dyn A-(1-13)NH2 showed a significant decrease in opioid
activity when compared to either its parent peptide [Lys6]Dyn A-(1-13)NH2 or Dyn A-
(1-13)NH2. [Lys9]- and [Lys(Ac)9]Dyn A-(1-13)NH2, which were very potent
analogues in the x and R, binding assays, exhibited potency similar to Dyn A-(1-13)NH2
in the GPI. Overall, the replacement of the basic residues by Lys(Ac) was better
tolerated than replacement by Ala, which caused at least a 7-fold decrease in activity in
the GPI.58 The antagonism of selected analogues by norbinaltorphimine, a x-selective
antagonist,67,68 was examined in order to evaluate whether these peptides were acting
on lc receptors in the GPI. Norbinaltorphimine at a dose of 10 nM consistently shifted
the dose-response curves of [Lys6]-, [Lys(Ac)6]-, [Lys9]-, [Lys(Ac)9]Dyn A-
(1-13)NH2 and Dyn A-(1-13)NH2 20- to 30-fold, indicating that the agonist activity of
these compounds in the GPI is mediated at least in part by tc receptors.27
Conclusions and Discussion
The above results have clear implications for the design of future Dyn A
analogues, particularly the design of conformationally constrained peptides. Our results
for [Lys(Ac)6]Dyn A-(1-13)NI-12 demonstrate that Arg6 is a key determinant in the
"address" sequence of Dyn A for the peptide's receptor selectivity profile. As
mentioned above, the importance of this residue was not revealed by the earlier studies
of truncated sequences.57,58 While a basic residue at position 6 in Dyn A is not required
for x receptor binding, it decreases the peptide's interactions with [t and 6 receptors,
enhancing lc selectivity. These results suggest that cyclization through this position to
give conformationally constrained analogues could have an adverse affect on selectivity
for lc receptors. Of the five basic residues in the "address" sequence, our data indicate
that only Arg9 can easily be replaced by a nonbasic amino acid without substantial loss
of lc receptor selectivity, making this is a logical site for incorporation into a
conformational constraint. Our results for substitution of the remaining basic residues in
positions 7, 11, and 13 are consistent with the earlier observations that these residues
are important for tc receptor affinity and selectivity.57
Experimental Section
Materials. The reagents used in peptide synthesis were as follows: FmocPAL
Resin (MBHA resin with a 544-(Fmoc-aminomethyl)-3,5-dimethoxyphenoxylvaleric
acid linker), HOBt and all amino acids except FmocLys and FmocLys(Ac)
(Milligen/Biosearch, Novato, CA); FmocLys (Bachem, Torrence, CA); TFA (Kali-
Chemie, Greenwich, CT); anisole, ethanedithiol, and DIC (Aldrich); acetic anhydride
(Baker); and HPLC-grade solvents DCM, DMF, DMA, Me0H (Burdick and Jackson
or Merck Omnisolv). The reagents and supplies used in purification were as follows:
HPLC-grade AcCN and Me0H (Burdick and Jackson); TFA (Pierce Sequanal grade in28
amber ampules); HPLC-grade water (Milli-Q system, College of Pharmacy); Syrfil
disposable HPLC filters, 0.45 tirn pore size. Other reagents were reagent grade.
FmocLys(Ac) was prepared initially by acetylation of FmocLys with acetic
anhydride (6 equiv) in DMF for 3 h, followed by evaporation, trituration with ether, and
recrystallization from EtOAc. Subsequently FmocLys(Ac) was obtained from Peninsula
Laboratories, Belmont, CA. The melting points (156-158° C) and analytical HPLC (R,
= 39.5 mL, 0 to 75% B over 50 min) were identical for the two samples.
The peptides were synthesized on a Biosearch 9500 automated peptide synthesizer
(Novato, CA). The peptides were analyzed using a Beckman Model 431A gradient
HPLC system consisting of a Model 421A controller, two Model 110B pumps, Model
201A injector, Model 163 detector, and a Waters Model 740 data module. The peptides
were purified on the above system with an ISCO UA-5 UV detector, or on a Rainin
HPLC gradient system with HPLX pumps and the ISCO detector. The HPLC columns
used were a Vydac 214TP54 C4 analytical column (300A, 5 rum, 4.6 mm x 25 cm) with
a Vydac C4214TP guard cartridge, and a Protein Plus preparative column (300A, 10
rim, 21 mm x 25 cm) with a Dynamax (21 mm x 5 cm, C4, 12 Rm) guard cartridge.
The peptides were eluted using 0.1% TFA in H2O (Solvent A) and 0.1% TFA in AcCN
(Solvent B). For the analytical and preparative columns the flow rateswere 1.5
mL/min. and 10 or 20 mU min, respectively, and the eluents were monitored at 214nm
(Beckman Model 163 detector) and 280 nm (ISCO UA-5 detector), respectively. The
aqueous solutions were lyophilized on a Thermovac Model FD-6 lyophilizer.
The peptides were characterized by FAB-MS and amino acid analysis. The FAB-
MS was performed on a Kratos MS5ORF in the Department of Agricultural Chemistryat
Oregon State University, Corvallis, OR. Peptide sampleswere hydrolyzed for 24 h at
110° C with 6 N HC1 plus 1% phenol and amino acid content determined by the Center
for Gene Research and Biotechnology, Central Services Laboratory, Oregon State29
University, on a Beckman System Gold Model 126AA (2 x 250 mm Spherogel
column), using ninhydrin detection at 570 nm.
Peptide Synthesis using Fmoc-protected Amino Acids
Solid Phase Peptide Synthesis.All peptides were synthesized
using the Fmoc chemical protocol on the Biosearch 9500. The FmocPAL resin (0.5 g,
0.27 mmol/g resin substitution) was washed with 5 x 20 mL of DCM/DMF (1/1) and
the synthesis carried out as follows: the deprotection of the resin was performed for 3
min, then 7 min in piperidine/toluene/DMF (30/35/35, v/v), and the resin then washed
with DCM/DMF (1/1, 12x). The solution of the desired Fmoc amino acid (0.4 M in
DMF, 4.0-fold excess) with 1 equivalent of HOBt was mixed with an equal amount of
0.4 M DIC in DCM and reacted with the resin for 2 h; the resin was then washed with
DCM/DMF (1/1, 12x). Amino acids with side chain protecting groups used were
FmocArg(Pmc), FmocLys(Boc), and FmocTyr(tBu). Ninhydrin was used on a small
sample of resin to determine if couplings were complete. Following a coupling reaction
the Fmoc group was removed as described above and the next amino acid coupled to the
resin. After completion of the peptide assembly and removal of the Fmocgroup from
the N-terminal residue, the resin was washed successively with DCM/DMF (1/1),
DCM, and Me0H, collected and dried overnight in vacuo. DMAwas used in place of
DMF in the synthesis of [Lys(Ac)71- and [Lys(Ac)13]Dyn A-(1-13)NH2.
Cleavage of the Peptide from the Support.The dried protected
peptide resins were generally reacted at room temperature with 5 mL Reagent K62
(82.5% TFA, 5% water, 5% phenol, 5% thioanisole, and 2.5% ethanedithiol) under
nitrogen for 4-5 h. The peptides were filtered from the resin, washed with TFA and
concentrated to about 2-5 mL. The solutions were diluted with 10% acetic acid (40 ml)30
and then extracted with Et20 (3x), and the aqueous layers lyophilized to give the crude
peptides. 1Lys6J1Dyn A-(1-13)NH2 was obtained by treating the corresponding resin
with 5 mL Reagent R60 (90% TFA, 5% thioanisole, 3% ethanedithiol, and 2% anisole)
under nitrogen for 24 h, followed by filtration, concentration, and trituration of the
peptide with ether. [Lys(Ac)6]Dyn A-(1-13)NH2 was cleaved from the resin using
TFA/anisole (9/1) overnight, followed by filtration, concentration, and trituration with
ether.
Purification of the Peptides.The crude peptides were purified by
preparative HPLC using a mobile phase gradient of either 100% A to 50% Bover 50
min at 20 ml/min or 100% A to 70% B over 140 min at 10 ml/min. [LysiDyn A-(1-
13)NH2 required a second purification by preparative HPLC. Generally peak fractions
were analyzed by isocratic analytical HPLC and pure fractions combined and
lyophilized. The resulting pure peptides were characterized by FAB-MS, amino acid
analysis, and analytical HPLC (Tables 2 and 3).
Binding Assays. Guinea pig cerebellar membranes and rat forebrain
membranes were prepared as previously described.66 (See Appendix A.) The inhibition
of the binding of [3H]bremazocine to guinea pig cerebellar membranes (lc)was
measured at 40C in the presence of bestatin as previously reported,66 except that 100
nM DAMGO was included in the incubation mixtures. Nonspecific bindingwas
determined in the presence of 1 ILM Dyn A-(1-13)NH2. The inhibition of the binding of
[3H]DAMGO (.t) and [3H]DPDPE (6) to rat forebrain membraneswas measured at 4D C
in the presence of peptidase inhibitors, as previously described;66 nonspecific binding
was measured in the presence of 10 RM levorphanol and 10 RM unlabeled DPDPE,
respectively. Equilibrium inhibition constants (K,'s)were calculated from the Cheng31
and Prusoff equation,69 using 0.0549, 0.314 and 7.63 nM for the KD values of tritiated
bremazocine, DAMGO, and DPDPE, respectively.
Guinea Pig Ileum Assay.Guinea pig ileum assays were performed as
previously described.66 (See Appendix A.) In experiments involving nor-
binaltorphimine, the antagonist was added to the tissue bath 20 min prior to
determination of the agonist dose-response curve.
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A Abbreviations
Abbreviations used for amino acids follow the rules of the IUPAC-IUB
Commission of Biochemical Nomenclature outlined in J. Biol. Chem. 1972, 247,
977-983. Amino acids are in the L-configuration. Additional abbreviations usedare as
follows: ACCA, 4-aminocyclohexanecarboxylic acid; Aib, aaminoisobutyric acid;
DAMGO, [D-A1a2,MePhe4,Glyol]enkephalin; DPDPE, [D-Pen2,D-Pen5]enkephalin;
Dyn A, dynorphin A; FAB-MS, fast atom bombardment mass spectrometry; Fmoc, 9-
fluorenylmethoxycarbonyl; Fmoc-ON-Su, N-9-(fluorenylmethoxycarbony1)-
succinimide; GPI, guinea pig ileum; TFA, trifluoroacetic acid; TIC, tetrahydrofuran.34
Abstract
It has been proposed that the "message" sequence of dynorphin A (Dyn A) exists
in an extended conformation in aqueous solution (Schiller, P.W. Int. J. Pept. Protein
Res. 1983, 21, 307-312). Molecular modeling suggested that trans-4-aminocyclo-
hexanecarboxylic acid (trans-ACCA) might function as a conformationally constrained
replacement for Gly2-Gly3 of Dyn A in such an extended conformation. ACCAwas
synthesized by catalytic hydrogenation of p-aminobenzoic acid and the cis and trans
isomers were separated by fractional recrystallization. Analogues of Dyn A-(1-13)NH2
containing cis- and trans-ACCA were prepared by solid-phase peptide synthesis using
the Fmoc chemical protocol. Results from radioligand bindingassays indicated that the
peptides have modest affinity for K opioid receptors (Ki's= 9.1 and 13.4 nM for [cis-
ACCA2-3]- and [trans-ACCA2-3]Dyn A-(1-13)NH2, respectively) and modest)(-
receptor selectivity (K, ratio (Kitt/6) = 1/13/210 and 1/21/103, respectively). [cis-
ACCA2-3)- and [trans-ACCA2-31Dyn A-(1-13)NH2 are the first reported Dyn A
analogues constrained in the "message" sequence that are selective forK receptors. The
cis-ACCA analogue showed very weak opioid activity (IC50= 4.0 !AM) in the guinea
pig ileum.35
Introduction and Rationale
Dynorphin A (Dyn A), a 17-amino acid peptide, has been postulated to be an
endogenous K opioid receptor ligand.42 Dyn A shares with other mammalian opioid
peptides a common N- terminal tetrapeptide "message" sequence which is important for
opioid activity, while containing a unique C-terminal "address"sequence which imparts
selectivity for K opioid receptors.41 The shortened Dyn A-(1-13), with thesequence
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys, accounts for essentially all of
the biological activity of Dyn A in the guinea pig ileum (GPI) assay.56
Since Dyn A is a linear peptide, it can adopt a number of possible conformations
in solution, with the conformation dependent on the environment. In aqueous solution
several spectral techniques, circular dichroism,4344 IR spectroscopy,45.46 Raman
spectroscopy,47 and NMR,46,48,49 are consistent with a random coil and/or extended (3-
strand conformation for Dyn A-(1-13). Fluorescent energy transfer experiments with
[Trp4]Dyn A-(1-13) in dilute aqueous solution suggested that the N-terminal portion of
Dyn A is in an extended conformation.50 On the planar surface ofa neutral lipid
membrane,45 or in the presence of sodium dodecyl sulfate,43 however, Dyn A-(1-13)
appears to adopt an a-helical structure. Binding to an anionic phospholipid48 or the
addition of cerebroside sulfate44 does not induce helical structure in the peptide.
The question remains of whether a conformation observed in solution reflects the
conformation Dyn A adopts at opioid receptors. Preparing conformationally constrained
derivatives is another way to examine the biologically active conformations ofa peptide.
The two reported analogues of Dyn A constrained in the "message"sequence, cyclof1D-
Cys2,Cys5iDyn A-(1-13)51 and cyclo[D-Orn2,Asp5]Dyn A-(1-8),52 show highpotency
in the GPI, but also exhibit high R-receptor affinity. The other reported cyclic analogues
of Dyn A, cyclized via either a lactam52 or a disulfide,53are constrained in the C-
terminal "address" portion of the peptide.36
Since the N-terminal "message" sequence appears to be important for the opioid
activity of Dyn A, we incorporated conformational constraints into this region of the
peptide. Tyr' and Phe4 residues are important for opioid activity and potency,-+' so
conformational constraints involving Gly2 and/or Gly3, which would affect the relative
orientation of the aromatic rings at positions 1 and 4, were examined. Since several of
the conformational studies described above, particularly Schiller's fluorescent energy
transfer experiments,50 suggested an extended conformation for the N-terminus of Dyn
A, a conformational constraint consistent with this proposed conformation was chosen
for preparation.
Results and Discussion
Design Rationale and Synthesis.Molecular modeling with the
AMBERArlprogram was used to examine possible conformational constraints for
incorporation into positions 2 and 3 in Dyn A-(1-13)NH2. These studies suggested that
trans-4-aminocyclohexanecarboxylic acid (trans-ACCA) might replace Gly2-Gly3 inan
extended conformation. The calculated nitrogen-carbonyl carbon distancewas 5.70A
for trans-ACCA in the diequitorial conformation vs. 6.12A between the nitrogen of Gly2
and the carbonyl carbon of Gly3 when the peptide was in an extended conformation.
The ACCA dipeptide replacement is equivalent to constrainingi2 and 43 while still
allowing free rotation around dp2 and 14 3. (Fig. 6.)
ACCA was synthesized by hydrogenation of p-aminobenzoic acid with Pt02as a
catalyst72 (Fig. 7), which yielded a mixture of cis and trans isomers (approx. ratio of
2.5/1 cis/trans). Separation by fractional recrystallization73 from EtOH yielded the cis
isomer, which was pure by 'H -NMR. Subsequent recrystallization from Et0H/ether
yielded the trans isomer, but 'H -NMR indicated that the trans isomer contained from 10-
15% up to 35% of the cis isomer, depending on the batch. Following fractionalFig. 6. Dyn A- and [trans-ACCA"]Dyn A-(1-13)NH2
Tyr-NH
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-LysN H2
Dyn A-(1-13)NH2
....47CO-Phe-Leu-Arg-Arg-Ile -Arg-Pro -Lys-Leu-LysNH2
[trans-ACCA2-3]Dyn A-(1-13)NH238
Fig. 7. ACCA Synthetic Scheme
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recrystallization, each isomer was converted separately to its Fmoc (9-fluorenyl-
methoxycarbonyl) derivative. Fmoc protection of these branched amino acids proved to
be difficult, and literature procedures74 had to be modified75 to obtain the desired
product (see Experimental Section). HPLC verified that Fmoc-cis-ACCA contained
only the cis isomer. In the case of Fmoc-trans-ACCA, the contaminating cis isomer (RI
= 293 min) was not well resolved from the desired Fmoc-trans-ACCA (R1= 29.7 min)
by HPLC, so this mixture was used in the synthesis of the trans-ACCA analogue of
Dyn A-(1-13)NH2.
Both the cis and trans isomers were incorporated separately into Dyn A-(1-
13)NH2 (Fig. 7). The peptides were prepared as amides because of the enhanced
metabolic stability of Dyn A-(1-13) amide vs. its corresponding acid.59 The peptides
were synthesized on a PAL resin60 using Fmoc-protected amino acids by procedures
described previously.76 (See Chap I.) The peptides were deprotected and cleaved from
the PAL resin using trifluoroacetic acid (TFA), and purified by preparativereverse phase
HPLC. The purification of [cis-ACCA2-3]Dyn A-(1-13)NH2was straightforward,
while the purification of the trans analogue proved difficult due to the necessity of
separating it from the contaminating cis analogue. This resulted ina very low yield of
pure [trans ACCA2 -3]Dyn A-(1-13)NH2.
Opioid Receptor Binding Affinities and Opioid Activity.The
peptides were evaluated for opioid receptor affinity atlc receptors by measuring the
inhibition of binding of [3H]bremazocine to guinea pig cerebellar membranes, and for
and b receptor affinities in rat forebrain membranes using[3H]DAMGO ([D-
Ala2,MePhe4,Glyol]enkephalin) and [3H]DPDPE ([D-Pen2,D-Pen5]enkephalin),
respectively (Table 6).Table 6.Opioid Receptor Binding Affinities of Dyn A-(1-13)NH2 and [ACCA]Dyn A-(1-13)NH2 Analogues
ici (nM)
Analogueus_ PH]Bremazocine (K) P1JDAMGO (a) [31-1]DPDPE (6) Ratio K/11/61
Dyn A-(1-13)NH2 0.146 + 0.004 0.194 + 0.002 3.88 + 0.09 1/1.3 / 27
[cis-ACCA2-3]Dyn A-(1-13)NH2 9.10+ 0.92 117+ 2 1910+ 65 1/13 /210
[trans-ACCA2-3]Dyn A-(1-13)NH2 13.4+ 0.6 275+ 2 1370+ 53 1/21/103
1 Ratio of Kiic/KiliKio41
Both [cis-ACCA2-3]- and [trans-ACCA2-31Dyn A-(1-13)NH2 bound to K opioid
receptors with modest affinity (K1= 9-13 nM), with the cis-ACCA analogue exhibiting
slightly greater affinity than the trans isomer. The affinity of these analogues for lc
receptors is 1/60 to 1/90 that of the parent peptide Dyn A-(1-13)NH2. Introduction of
either isomer of ACCA into Dyn A-(1-13)NH2 causes an even larger decrease in affinity
for it receptors, resulting in K,'s greater than 100 nM. Therefore, both of these
analogues are K selective, with [trans ACCA2 -3JDyn A-(1-13)NH2 showing slightly
better K selectivity (Wit ratio = 1/21) than [cis ACCA2 -3JDyn A-(1-13)NH2 (x/it ratio =
1/13). Both of these peptides had very little affinity for 6 receptors (Ic's >1,000 nM).
Both the cis- and trans-ACCA Dyn A analogues show binding affinity similar to
the Dyn A-(1-13)NH2 analogues containing an L-amino acid at position 2 reported by
Story, et al.,66 all of which had K,'s in the 2-20 nM range. The ACCA substituted
peptides, however, have better x vs. it selectivity than any of these 2-substituted
dynorphin analogues. [Aib2]Dyn A-(1-13),77 which incorporates an a,a-disubstituted
amino acid into position 2 similar to the disubstitution a to the amine of ACCA,
surprisingly has lower affinity for lc receptors (K,,, = 50 nM). [Aib2]Dyn A-(1-13) has
10- to 30-fold higher affinity for it receptors (Kii.,-10 nM) than [cis-] and [trans-
ACCA2-3]Dyn A-(1-13)NH2; thus, the Aib2-substituted peptide is it selective while the
ACCA-substituted peptides are lc selective.
[cis-ACCA2-3JDyn A-(1-13)NH2 was evaluated for opioid activity in the guinea
pig ileum (GPI) assay. Its potency (IC50 4.09 itM, 95% confidence= 2.88-5.80 itM)
was much lower than the parent Dyn A-(1-13)NH2 (IC50 0.24 nM, 95% confidence =
0.21-0.29 nM), but this analogue exhibited a full dose-response curve and naloxone
antagonized its effects (data not shown.) The low GPI activity of [cis-ACCA2-31Dyn A-
(1-13)NH2 parallels the results obtained for the analogues containing L-amino acids in
position 2 .66 There was insufficient trans compound to allow for its testing in the GPI.42
Conclusions
[Cis -1 and [trans -ACCA2-31Dyn A-(1-13)NH2 are the first reported Dyn A
analogues conformationally constrained in the "message" sequence that are selective for
opioid receptors. The cis- and trans-ACCA2-3-substituted peptides showed
surprisingly similar lc, R, and 6 affinities when compared to each other and to Dyn A
analogues containing an L-amino acid in position 2.66 These results suggest that the
Gly2-Gly3 peptide bond is not critical for lc opioid receptor affinity or selectivity. The
similar binding affinities of the cis- and trans-ACCA Dyn A analogues, however, make
it difficult to make conclusions concerning the bioactive conformation of the "message"
sequence of Dyn A. The differences observed in receptor affinities and selectivity
between the x-selective [cis-ACCA2-3]- and [trans-ACCA2-31Dyn A-(1-13)NH2 and the
n-selective Dyn A analogue [Aib2]Dyn A-(1-13)77 could be due to differences in
conformation, the larger size of ACCA vs. Aib, or the substitution at the position
corresponding to the Cc, of Gly3 in the ACCA-substituted peptides.
The good discrimination of K vs. n receptors exhibited by the cis- and trans-
ACCA derivatives of Dyn A-(1-13)NH2 is encouraging and suggests that further
modification at positions 2 and/or 3 might lead to Dyn A analogues with higher lc
receptor affinity and opioid potency.
Experimental Section
Materials. The reagents and instrumentation used were those described
previously.76 (See Chap I.) Elemental analysis was performed by MWH Laboratories,
Phoenix, AZ. NMR spectroscopy was done on a 400 MHz Bruker NMR in the
Department of Chemistry at Oregon State University.43
Hydrogenation of p-aminobenzoic acid to ACCA.72 p-Aminobenzoic
acid (Aldrich, 1.056 g, 7.71 mmol) in 30% EtOH (100 mL) was hydrogenated under 50
psi H2, with Pt02 (278 mg) as a catalyst, at room temperature overnight. This was
repeated six times and the solutions combined. After removing the platinum by
filtration, the filtrate was concentrated in vacuo until crystals appeared. The crystals
were dissolved in H2O and boiled, and the solution was treated with charcoal. ACCA
was precipitated by the addition of 55 mL EtOH/ether (10/1), followed by additional
ether until no more crystals appeared. This yielded 4.916 g (70.7%) of ACCA as a
mixture of cis and trans isomers; TLC: Rf (C18, reverse phase, Me0H/H20, 60/40)
0.33.
Separation of cis and trans isomers of ACCA.73 The crystals were
dissolved in water and EtOH was added to crystallize cis-ACCA. The crystals were
collected and the process was repeated 3 times to obtain additional cis isomer. The
remaining filtrate was concentrated and 55 mL EtOH/ether (10/1) added to crystallize the
trans-ACCA.The crystals were collected and the process was repeated 3 times with the
addition of excess ether. The isomers were then recrystallized from H20/Et0H (cis) or
H2O /EtOH/ether (trans) to yield 3.125 g (44.9%) of cis-ACCA and 1.259 g (18.1%) of
trans-ACCA. Data for cis-ACCA follow: Mp: 258-264°C. FAB-MS: m/z 144 (M+1).
114 NMR (d-TFA): 6 1.76-2.34 (m, 8H, -CH2CH2-), 2.85 (m, 1H, -CHCO2H), 3.53
(m, 1H, -CHNH2). Anal. (C7H13NO2 0.4 H20): C, H, N. (See Appendix B.) HCI
salt mp: 207-208°C (lit. mp: 217°C73). Data for trans-ACCA follow: Mp: 262
267°C. FAB-MS: m/z 144 (M+1). Iff NMR (d-TFA): 6 1.60-1.70 (m, 4H, -CH2-),
2.33 (m, 4H, -CH2-), 2.52 (m, 1H, -CHCO2H), 3.46 (m, 1H, -CHNH2). Anal.
(C7H13NO2 0.4 H20): C, H, N. (See Appendix B.) HC1 salt mp: 272-273°C (lit.
mp: 273°C73).44
Fmoc-cis- and Fmoc-trans-ACCA.75 Cis-ACCA (393 mg, 2.73 mmol)
and NaOH (109 mg, 2.73 mmol) were dissolved in H2O (1.97 mL). A suspension of
Fmoc-ON-Su (Bachem, 737 mg, 2.18 mmol) in THF (1.97 mL) was added to the
ACCA solution, followed by additional H2O and THF (1.97 mL of each). After 5 min
NaHCO3 (229 mg, 2.73 mmol) and THF (1.97 mL) were added; all reactants went into
solution after 25 min. The reaction was stirred until TLC (CHC13/MeOH/AcOH, 89/
10/1) indicated that all of the Fmoc-ON-Su had reacted (overnight). The solution was
then acidified with excess 1.5 N HC1 and the product, which precipitated out, dissolved
in EtOAc. The HCl layer was extracted with additional EtOAc. The combined EtOAc
extracts were then washed with 1.5 N HC1 (2X), H2O (2X), and saturated NaCl and
dried over anhydrous MgSO4 or Na2SO4. The solvent was evaporated invacuo to give
a thick oil. Dissolution in EtOAc, precipitation with hexane, and evaporation of solvent
yielded 737 mg (92.6%) of Fmoc-cis-ACCA as a glassy solid. Mp: 128-130°C. FAB-
MS: m/z 366 (M+1). HPLCA (0 to 75% B over 50 min, 1.5 mL/min): Rl= 29.3 min.
1H NMR (d6- DMSO): to 1.40-1.58 (m, 6H, -CH2CH2-), 1.85 (m, 2H, -CH2-), 2.38
(br s, 1H, -CHCO2H), 3.41 (m, 1H, -CHNH-), 4.22 (m, 3H, Fmoc -CHCH20-),
7.29 (d, 1H, -NH-), 7.31 (t, 2H, Ar), 7.40 (t, 2H, Ar), 7.69 (d, 2H, Ar), 7.87 (d, 2H,
Ar). Anal. (C22H23N04): C, H, N. (See Appendix B.)
Protection of the trans isomer (429 mg, 3 mmol) as described for cis-ACCA
yielded 760 mg (86.7%) of Fmoc-trans-ACCA. FAB-MS: m/z 366 (M+1). HPLCA (0
to 75% B over 50 min, 1.5 mL/min): Rt = 29.7 min (Fmoc-trans-ACCA, 66%), Rt=
293 min (Fmoc-cis-ACCA, 33%). Data for an analytical sample recrystallized from
THF/H20 follow. Mp: 220-227°C. Iff NMR (d6- DMSO): 6 1.19-1.35 (m, 4H,
CH2CH2-), 1.85-1.94 (m, 4H, -CH2CH2-), 2.08 (br t, 1H, -CHCO2H), 3.18 (m, 1H,
CHNH-), 4.20 (m, 1H, Fmoc CHCH2O -), 4.26 (m, 2H, Fmoc -CHC1:120-), 7.22 (d,45
1H, -NH-), 7.32 (t, 2H, Ar), 7.40 (t, 2H, Ar), 7.67 (d, 2H, Ar), 7.87 (d, 2H, Ar).
Anal. (C22H23N04): C, H, N. (See Appendix B.)
Peptide Synthesis using Fmoc-protected Amino Acids.Both peptides
were synthesized, cleaved from the resin, and purified by procedures described
previously.76 (See Chap I.) Before removing the Fmoc group from ACCA, the entire
coupling sequence for that amino acid was repeated to ensure complete coupling.
Following cleavage from the resin the peptides were purified by preparative reverse
phase HPLCB (0 to 50% B over 75 min, 20 mUmin for the cis analogue, and 15 to 45%
B over 60 min, 20 mL/min for the trans analogue). Data for [cis-ACCA2-3]Dyn A-(1-
13)NH2 follow. Yield: 30 mg (24%). FAB-MS: m/z, 1614 (M+1). HPLCA (0 to 75%
B over 50 min, 1.5 mL/min): Rt = 19.5 min. Amino acid analysis: Tyr (1) 0.93, Phe
(1) 0.99, Leu (2) 2.02, Arg (3) 3.15, Ile (1) 0.97, Pro (1) 0.97, Lys (2) 2.01. Data for
[trans ACCA2 -3]Dyn A-(1-13)NH2 follow. Yield: 4.4 mg (3.3%). FAB-MS: mlz
1614 (M+1). HPLCA (15 to 35% B over 40 min, 1.5 mUmin): Rt = 14.4 min. Amino
acid analysis: Tyr (1) 0.79, Phe (1) 1.05, Leu (2) 2.02, Arg (3) 3.12, Ile (1) 0.99, Pro
(1) 1.02, Lys (2) 2.02.
Binding and Guinea Pig Ileum Assays.Guinea pig cerebellar membranes
and rat forebrain membranes were prepared and binding assays performed as previously
described,66 (Appendix A) except that 100 nM DAMGO was included in the incubation
mixtures of [3H]bremazocine with guinea pig cerebellar membranes (ic binding assays).
Guinea pig ileum assays were performed as previously described.66 (See Appendix A.)
In experiments involving naloxone, the antagonist was added to the tissue bath 10 min
prior to determination of the agonist dose-response curve.46
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AcCN.
B Protein Plus preparative column, solvents A and B are as above.47
Conclusion
Designing an opioid drug with less abuse potential and fewer side-effects may still
lie quite a distance in the future, but our understanding of the requirements that must be
met grows each day. The findings in Chapters I and II may be small, but make
significant contributions to this understanding. The study in Chap. I involved
eliminating each of the positive charges in positions 6, 7, 9, 11, and 13 in Dyn A-(1-
13)NH2 by replacing each of the amino acids in these positions by Lys(Ac). The results
indicated that Arg9 is the only residue that could be replaced by a non-basic amino acid
without losing x-selectivity or potency. Therefore, this would be a good position
through which to incorporate a conformational constraint in further studies of the
"address" sequence of Dyn A. When the charge at positions 7, 11, or 13 is removed, all
ic-selectivity is lost, so these positions are not options to alter further. Although
removing the charge at position 6 lowers the opioid potency and makes [Lys(Ac)6]Dyn
A-(1-13)NH2 nonselective for -lc vs.It receptors, it still retains high binding affinity.
This means altering this position, with or without retention of the positive charge, could
possibly lead to useful pharmacological tools in further studies.
Chapter II described the synthesis and pharmacological evaluation of the first
reported analogues of Dyn A constrained in the "message" sequence that are selective for
K opioid receptors. When Chapter II was published, it still was not clear what could be
concluded about the "message" sequence of Dyn A since the cis- and trans-ACCA-Dyn
A analogues showed very similar receptor affinities. With further consideration several
possibilities have become apparent. In light of the low affinity of these compounds, it is
possible that an interaction between the peptide and receptor (for examplea hydrophobic
or van der Waals interaction with one of the aromatic rings) has been significantly
disrupted in both analogues so that the remaining interactionsare the same. Another48
possible explanation of the similar affinities of [cis]- and [trans-ACCA2-3]Dyn A-(1-
13)NH2 for opioid receptors is that, with free rotation around the bonds in residues 1
and 4, the aromatic rings of Tyr' and Phe4 could have similar orientations at the receptor
binding site regardless of whether cis- or trans-ACCA is in positions 2-3.
More importantly, in our initial analysis of the conformation of the "message"
sequence of Dyn A, we assumed that the cyclohexane ring in ACCA would
preferentially assume a chair conformation, as this is more thermodynamically stable
than the boat conformation. In this case, the trans-ACCA analogue should have an
angle of approximately 180° between Tyri and Phe4 (extended conformation; see Fig.
8), and the cis-ACCA analogue should have a 90° angle between Tyr' and Phe4 (bent ).
However, if the cyclohexane ring assumes a boat conformation, in the cis-ACCA
analogue the angle between Tye and Phe4 becomes approximately 180° as in the trans-
ACCA analogue. This could not only explain their similar binding data, but also
suggests that the "message" sequence of Dyn A is in an extended conformation. Using
the same reasoning and assuming the trans-ACCA ring is in a boat conformation, makes
its Tyr' to Phe4 angle 90°, but this possibility is even more thermodynamically unlikely.
Thus, the bioactive conformation of the "message" sequence of Dyn A is probably nota
bend or turn.Fig. 8. Ring Conformations
180
Tyr' -N
CO-Phe4-- -
trans-ACCA analogue
cis-ACCA analogue
Tyri-NH----\---.....--7CO-Phe4-- -
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Appendix A:Biological Assays
Binding Assays
Guinea Pig Brain Preparation and [3H]Bremazocine Binding Assay.
Frozen guinea pig brains obtained from Pel-Freez (Rogers, AR) were thawed on ice
before the cerebellum was dissected away. The guinea pig cerebelli, weighing
approximately 0.5 g, were suspended in 100 volumes ice-cold 20 mM HEPES, pH 7.4,
by Polytron (Brinkman Instruments) for 15 seconds at setting 7.5. The homogenate
was then centrifuged at 47,000 x g for 10 minutes at 40 C. The pellet was resuspended
in buffer, preincubated for 45 minutes at 370 C and then recentrifuged. The final pellet
was suspended in 100 volumes 20 mM HEPES, pH 7.4 and stored on ice until use in
the binding assay.
The [3H]bremazocine binding assays were carried out at 40 C for 3 hours. One
mL of tissue was added to borosilicate glass tubes containing bestatin at a final
concentration of 10 [LM and 20 RI, of peptide stock solution in increasing final
concentrations of 0.01 to 10,000 nM in a final incubation volume of 2 mL. The assay
was initiated with the addition of [3H]bremazocine at a final concentration of 0.75 nM.
Nonspecific binding was determined in the presence of 1 RM Dyn A-(1-13)NH2. The
binding reaction was terminated by rapid filtration over #32 glass filters (Scheicher &
Schuell) using a Brandel M24-R Cell Harvester. The filters were presoaked for 2 hours
in 0.5% polyethyleneimine to decrease nonspecific filter binding. The filter disks were
then placed in minivials with 4 mL Cytocint (ICN Radiochemicals) and allowed to elute
for 6 hours before counting in a Beckman LS6800 scintillation counter.60
Rat Forebrain Preparation and [3H]DAMGO and [3H]DPDPE
Assays. Frozen rat brains obtained from Pel-Freez (Rogers, AR) were thawed on ice
before the cerebellum and brain stem were removed and discarded. The rat forebrains,
weighing approximately 1.2 g, were suspended in 50 volumes ice-cold 50 mM Tris, pH
7.7, by Polytron for 15 seconds at setting 7.5. The homogenate was then centrifuged at
45,000 x g for 15 minutes at 40 C. The pellet was resuspended and recentrifuged in
buffer as in the previous step. The second pellet was resuspended in buffer and
preincubated for 45 minutes at 370 C, recentrifuged, and the final pellet was suspended
in 80 volumes 50 mM Tris, pH 7.7 to yield a concentration of 0.71.0 mg protein/mL,
as determined by the method of Lowry.78
The [3H]DAMGO and [3H]DPDPE binding assays were carried out at 40 C for 5
hours. One mL of tissue was added to borosilicate glass tubes containing bestatin,
captopril, and L-leucyl-L-leucine at final concentrations of 10, 30, and 50 [A,M,
respectively. A 20 ttL aliquot of peptide stock solution was added in increasing final
concentrations of 0.01 to 10,000 nM in a final incubation volume of 2 mL. The
DAMGO binding reaction was initiated with the addition of 035 nM [3H]DAMGO.
Nonspecific binding was determined in the presence of 10 IA,M levorphanol. The
reaction was terminated by rapid filtration over #32 glass filters (Scheicher & Schuell),
which had been presoaked for 2 hours in 0.5% polyethyleneimine as described above,
using a Brandel M24R Cell Harvester. The DPDPE binding reaction was initiated with
the addition of 2.5 nM [3H]DPDPE. Nonspecific binding was determined in the
presence of 10 iii,M unlabeled DPDPE and the reaction terminated by rapid filtration over
Whatman GF/C fiber filters, presoaked as described above, using a Brandel M24-R Cell
Harvester. The filter disks were then placed in minivials with 4 mL Cytocint, eluted for
6 hours, and counted in a Beckman LS6800 scintillation counter as described above.61
Data Analysis. Competition data were fit by nonlinear regression analysis
using the Public Procedure FITCOMP of the NIH Prophet Computer Resource, which
employs an iterative process to minimize residual least squares. The IC50 values derived
from competition analyses were converted to dissociation constants (K ) using the
Cheng and Prusoff equation;69 the KD values determined for tritiated bremazocine,
DAMGO and DPDPE were 0.0549 nM, 0.314 nM and 7.63 nM, respectively.
Guinea Pig Ileum Assay.Guinea pigs weighing approximately 400 g were
obtained from a commercial supplier (Simonsen, Gilroy, CA) and kept on a 12/12 h
light/dark schedule with free access to food and water. Vitamin C supplementation was
provided in water. Guinea pigs were killed by exposure to CO2 and segments of the
longitudinal muscle of the ileum were dissected free. Tissues were suspended in a 10
mL siliconized tissue bath in oxygenated Kreb's solution at 370 C. One gram of tension
was applied to the tissue before beginning field stimulation (80 mV, 0.1 Hz, 0.5 sec
duration). Peptidase inhibitors were initially investigated, but discontinued when no
significant differences were observed with and without inhibitors for this series of
dynorphin analogues.
Agonist activity was determined by observing inhibition of stimulated contractions
with cumulative doses of dynorphin analogues added to the bath. Mean IC50 values
were determined from 3 6 replications using tissues from different guinea pigs. Dyn A-
(1-13)NH2 IC50 values were determined as a control for each tissue following
determination of the IC50 value for each test compound. Data from experiments in
which tissues did not recover to at least 75% of maximal peak height after analogue
treatment or experiments in which IC50 values for Dyn A-(1-13)NH2 were abnormal
were not used.62
Appendix B:Analytical Data
Elemental Analysis of cis- and trans-ACCA
MW cis-ACCA 0.4 H2O = MW trans-ACCA 0.4 H2O = 150.3
ELEMENT THEORETICAL % % cis-ACCA % trans-ACCA
C 55.8 55.9 55.9
H 9.2 9.3 8.8
N 9.3 9.7 9.3
Elemental Analysis of Fmoc-cis- and Fmoc-trans-ACCA
MW Fmoc-cis-ACCA = MW Fmoc-cis-ACCA = 365.0
ELEMENTTHEORETICAL %% Fmoc-cis-ACCA% Fmoc-trans-ACCA
C 72.3 72.4 72.1
H 6.4 6.4 6.3
N 3.8 3.8 3.8